ELEDON PHARMACEUTICALS INC. - COMMON STOCK

4,2900

21-февраля-25 16:45:00

15 мин. задержка

Акции

-0,0500

-1,15%

Сегодняшний диапазон

4,2300 - 4,3906

ISIN

N/A

Источник

NASDAQ

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

07 фев 2025 10:00:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

29 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

13 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

12 ноя 2024 16:01:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

06 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

29 окт 2024 07:46:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

29 окт 2024 07:45:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

11 сен 2024 16:05:00 Источник Nasdaq GlobeNewswire
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

04 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

14 авг 2024 17:21:26 Источник Nasdaq GlobeNewswire
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

29 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

02 июл 2024 16:05:00 Источник Nasdaq GlobeNewswire
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

03 июн 2024 16:01:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

09 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

09 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

07 май 2024 07:05:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement

07 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

28 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

25 мар 2024 16:56:42 Источник Nasdaq GlobeNewswire
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

21 мар 2024 10:31:12 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.